DOCSLIB.ORG

Type I Interferons in Anticancer Immunity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Type I Interferons in Anticancer Immunity REVIEWS Type I interferons in anticancer immunity Laurence Zitvogel1–4*, Lorenzo Galluzzi1,5–8*, Oliver Kepp5–9, Mark J. Smyth10,11 and Guido Kroemer5–9,12 Abstract | Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic 1Gustave Roussy Cancer Campus, F-94800 Villejuif, viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the France. intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with 2INSERM, U1015, F-94800 Villejuif, France. favourable disease outcome in several cohorts of patients with cancer. Finally, new 3Université Paris Sud/Paris XI, anticancer immunotherapies are being developed that are based on recombinant type I IFNs, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. type I IFN-encoding vectors and type I IFN-expressing cells. 4Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif, France. Type I interferons (IFNs) were first discovered more than Type I IFNs in cancer immunosurveillance 5Equipe 11 labellisée par la half a century ago as the factors underlying viral inter­ Type I IFNs are known to mediate antineoplastic effects Ligue Nationale contre le ference — that is, the ability of a primary viral infection against several malignancies, which is a clinically rel­ Cancer, Centre de Recherche 1 des Cordeliers, F-75006 Paris, to render cells resistant to a second distinct virus . Type I evant activity that has been attributed to their immuno­ 8 France. IFNs comprise IFNα proteins (a class of homologous pro­ stimulatory functions . However, the precise role of type I 6INSERM, U1138, F-75006 teins that are encoded by 13 distinct genes in humans, IFNs in the natural immune response to cancer has only Paris, France. IFNA1 to IFNA13), IFNβ (that is encoded by a single begun to be understood in the past decade. Experimental 7 Université Paris Descartes/ gene in humans and mice, IFNB1) and other, less investi­ data strongly suggest the existence of a process whereby Paris V, Sorbonne Paris Cité, F-75006 Paris, France. gated IFNs, such as IFNε, IFNκ and IFNω, which will not the immune system, in the absence of external manipula­ 2,3 8Université Pierre et Marie be discussed in this Review . Type I IFNs are produced tions, protects the host against oncogenesis and controls Curie/Paris VI, F-75006 Paris, by multiple cell types following activation of pattern the immunological features of developing tumours9. This France. recognition receptors (PRRs) (BOX 1). PRRs respond to process, which has been called cancer immunoediting, 9Metabolomics and Cell Biology Platforms, Gustave viral or bacterial components and also to endogenous consists of three phases: first, the elimination of malig­ Roussy Cancer Campus, mole­cules found in ectopic locations (such as cytosolic nant cells by the immune system; second, the establish­ F-94800 Villejuif, France. DNA and extracellular DNA and RNA)4. Type I IFNs ment of an equilibrium between genetically unstable 10Immunology in Cancer and signal via a homodimeric IFNα/β receptor 1 (IFNAR1), malignant cells and the immune system, which reflects Infection Laboratory, QIMR which has a particularly high affinity for IFNβ, or via the immunoediting imposed by the immune system Berghofer Medical Research Institute, Herston QLD 4006, an IFNAR1–IFNAR2 heterodimer, which binds all type I on cancer cells; and third, the escape of neoplastic cell Australia. IFNs. The activation of these receptors elicits many variants with reduced immunogenicity, which ulti­ 11School of Medicine, immunostimulatory effects (BOX 2) following the tran­ mately form clinically manifest neoplasms10. Type I IFNs University of Queensland, scriptional upregulation of IFN-stimulated genes (ISGs), intervene in all of these phases11,12. Herston QLD 4006, Australia. 5–7 12Pôle de Biologie, Hôpital some of which are also responsible for viral interference . At least some cell types produce type I IFNs and/or Européen Georges Pompidou, In this Review, we discuss the growing body of evi­ respond to them to avoid neoplastic transformation. AP‑HP, F-75015 Paris, France. dence suggesting that type I IFNs have a major role Indeed, the absence of Ifnb1 or Ifnar1 predisposes mouse *These authors contributed not only in antiviral immune responses but also in the embryonic fibroblasts to cellular transformation13, and equally to this work. natural and the therapy-induced immunological control some viral oncoproteins interfere with the functions of Correspondence to G.K. 14 e‑mail: [email protected] of virus-unrelated malignancies. These advances have ISGs . The tissue-specific deletion of Ifnar1 from intes­ doi:10.1038/nri3845 far-reaching implications for tumour immunology, drug tinal epithelial cells increases tumour burden in mice Published online 1 June 2015 development and clinical oncology. treated with the colitis-inducing agent dextran sodium NATURE REVIEWS | IMMUNOLOGY VOLUME 15 | JULY 2015 | 405 © 2015 Macmillan Publishers Limited. All rights reserved REVIEWS Box 1 | Sources and signals underlying type I IFN production The knockout of Ifnar1 or Ifnar2 increases the inci­ dence of methylcholanthrene (MCA)-induced fibro­ Plasmacytoid DCs (pDCs) produce high amounts of type I interferons (IFNs) following sarcomas in mice11,18. In this context, IFNAR1 must stimulation of Toll-like receptor 7 (TLR7) and TLR9, which detect viral RNA and DNA be expressed by the radiosensitive haematopoietic cell molecules, respectively, that have been endocytosed or sequestered by autophagy103. compartment to participate in immunosurveillance. pDCs are also capable of sensing host-derived nucleic acids; for instance, this occurs −/− in the context of skin wounds104. In this setting, the host DNA binds to cathelicidin Moreover, some MCA-induced Ifnar1 fibrosarcoma peptides, which promote the access of the nucleic acids to intracellular TLRs and cells were unable to form tumours following transfer to hence contribute to early inflammatory responses and re-epithelialization104. wild-type mice because they were rejected by the host (in Other sources of type I IFNs are well characterized. For instance, CD141+ which type I IFN signalling is intact)11. Taken together conventional DCs are prominent producers of IFNα in humanized mice following with the results obtained from models of mammary administration of polyinosinic–polycytidylic acid (polyI:C)105. Moreover, almost any carcinogenesis17, these findings suggest that in many cell in the body can synthesize type I IFNs upon activation of cytosolic receptors for instances cancer immunosurveillance does not rely double-stranded RNA (dsRNA), particularly the RNA helicases retinoic acid-inducible on the induction of IFNAR1 signalling in cancer cells. gene protein I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5). −/− + + Accordingly, Ifnar1 CD8α dendritic cells (CD8α DCs) RIG-I and MDA5 signal through mitochondrial antiviral-signalling protein (MAVS) and are deficient in antigen cross-­presentation, and mice TANK-binding kinase 1 (TBK1) to activate the IFN-regulatory factor 3 (IRF3)‑dependent transcription of type I IFN-coding genes2. Similarly, type I IFN can be produced upon lacking Ifnar1 only in this cellular compartment fail 19 the activation of stimulator of IFN genes protein (STING) and MAVS by the bacterial to reject highly immunogenic malignant cells . These second messenger cyclic di-GMP24. STING is also required for apoptotic thymocytes to results indicate that type I IFN signalling is a crucial com­ synthesize immunosuppressive factors, such as indoleamine 2,3‑dioxygenase 1 (IDO1), ponent of the innate immune response to transformed interleukin‑10 (IL‑10) and transforming growth factor‑β1 (TGFβ1), in vivo100, probably cells. Of note, this study19 identified a link between type I owing to its ability to drive type I IFN production. Consistent with this idea, type I IFNs IFNs and CD8α+ DCs that could explain the require­ stimulate the release of IL‑10 from regulatory T (TReg) cells and T regulatory type 1 cells ment for this antigen-presenting cell (APC) subset in (T 1 cells) in mice and humans106,107. Of note, the production of type I IFNs can be + R the spontaneous cross-priming of tumour-specific CD8 amplified by a positive feedback loop that involves the transactivation of IRF7 and, cytotoxic T lymphocytes (CTLs) in vivo20. Interestingly, at least in DCs, IRF8 in response to IFN / receptor (IFNAR) signalling. α β Reis e Sousa and colleagues21,22 showed a role for C‑type Cell death can influence immune responses as it is associated with the emission of danger signals that activate antigen-presenting cells (APCs). Several possible pattern lectin domain family 9 member A (CLEC9A) — which is + recognition receptors (PRRs) — including STING and TLRs, as well as C‑type lectin a plasma membrane receptor highly expressed by CD8α domain family 9 member A (CLEC9A) — and the autophagy-facilitated transfer of DCs — in the cross-­presentation of antigens from dying dead cell-associated antigens to APCs may be involved in the induction of type I IFNs and virus-infected cells, making it logical to pursue a in vivo25,108,109.
Load more

Recommended publications
  • Developments in Cancer Immunoediting
    Downloaded from http://www.jci.org on March 16, 2016. http://dx.doi.org/10.1172/JCI80004 REVIEW SERIES: CANCER IMMUNOTHERAPY The Journal of Clinical Investigation Series Editor: Yiping Yang From mice to humans: developments in cancer immunoediting Michele W.L. Teng,1,2 Jerome Galon,3 Wolf-Herman Fridman,4 and Mark J. Smyth2,5 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. 2School of Medicine, University of Queensland, Herston, Queensland, Australia. 3INSERM UMRS1138, Laboratory of Integrative Cancer Immunology, Paris, France. Université Paris Descartes, Paris, France. Cordeliers Research Centre, Université Pierre et Marie Curie Paris 6, Paris, France. 4Laboratory of Cancer, Immune Control and Escape, INSERM U1138, Cordeliers Research Centre, Paris, France. Université Pierre et Marie Curie, UMRS 1138, Paris, France. Université Paris Descartes, UMRS 1138, Paris, France. 5Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. Cancer immunoediting explains the dual role by which the immune system can both suppress and/or promote tumor growth. Although cancer immunoediting was first demonstrated using mouse models of cancer, strong evidence that it occurs in human cancers is now accumulating. In particular, the importance of CD8+ T cells in cancer immunoediting has been shown, and more broadly in those tumors with an adaptive immune resistance phenotype. This Review describes the characteristics of the adaptive immune resistance tumor microenvironment and discusses data obtained in mouse and human settings. The role of other immune cells and factors influencing the effector function of tumor-specific CD8+ T cells is covered. We also discuss the temporal occurrence of cancer immunoediting in metastases and whether it differs from immunoediting in the primary tumor of origin.
    [Show full text]
  • CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy
    cancers Review CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy Jennifer R. Richardson 1 , Anna Schöllhorn 1,2 ,Cécile Gouttefangeas 1,2,3,* and Juliane Schuhmacher 1,2 1 Department of Immunology, Institute for Cell Biology, University of Tübingen, 72076 Tübingen, Germany; [email protected] (J.R.R.); [email protected] (A.S.); [email protected] (J.S.) 2 Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, 72076 Tübingen, Germany 3 German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) Partner Site Tübingen, 72076 Tübingen, Germany * Correspondence: [email protected] Simple Summary: T cells bearing the co-receptor CD4 on their cell surface are a heterogeneous group of T lymphocytes that exert pro- or anti-inflammatory functions. Evidence from mouse models and cancer patients reveal that various CD4+ T cell subsets play an antagonistic role in the antitumor immune response. This review summarizes current knowledge on CD4+ T cell subsets, on how they impact tumor growth in patients, and which role these cells play in newest cancer immunotherapies. Abstract: Cancer immunotherapy activates the immune system to specifically target malignant cells. Research has often focused on CD8+ cytotoxic T cells, as those have the capacity to eliminate tumor cells after specific recognition upon TCR-MHC class I interaction. However, CD4+ T cells have gained attention in the field, as they are not only essential to promote help to CD8+ T cells, but are also able to kill tumor cells directly (via MHC-class II dependent recognition) or indirectly (e.g., via Citation: Richardson, J.R.; the activation of other immune cells like macrophages).
    [Show full text]
  • Type I Interferons and the Development of Impaired Vascular Function and Repair in Human and Murine Lupus
    Type I Interferons and the Development of Impaired Vascular Function and Repair in Human and Murine Lupus by Seth G Thacker A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Immunology) in The University of Michigan 2011 Doctoral Committee: Associate Professor Mariana J. Kaplan, Chair Professor David A. Fox Professor Alisa E. Koch Professor Matthias Kretzler Professor Nicholas W. Lukacs Associate Professor Daniel T. Eitzman © Seth G Thacker 2011 Sharon, this work is dedicated to you. This achievement is as much yours as it is mine. Your support through all six years of this Ph.D. process has been incredible. You put up with my countless miscalculations on when I would finish experiments, and still managed to make me and our kids feel loved and special. Without you this would have no meaning. Sharon, you are the safe harbor in my life. ii Acknowledgments I have been exceptionally fortunate in my time here at the University of Michigan. I have been able to interact with so many supportive people over the years. I would like to express my thanks and admiration for my mentor. Mariana has taught me so much about writing, experimental design and being a successful scientist in general. I could never have made it here without her help. I would also like to thank Mike Denny. He had a hand in the beginning of all of my projects in one way or another, and was always quick and eager to help in whatever way he could. He really made my first year in the lab successful.
    [Show full text]
  • Of Keeping and Tipping the Balance: Host Regulation and Viral Modulation of IRF3-Dependent IFNB1 Expression
    viruses Review Of Keeping and Tipping the Balance: Host Regulation and Viral Modulation of IRF3-Dependent IFNB1 Expression Hella Schwanke 1,2 , Markus Stempel 1,2 and Melanie M. Brinkmann 1,2,* 1 Institute of Genetics, Technische Universität Braunschweig, 38106 Braunschweig, Germany; [email protected] (H.S.); [email protected] (M.S.) 2 Viral Immune Modulation Research Group, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany * Correspondence: [email protected]; Tel.: +49-531-6181-3069 Received: 15 June 2020; Accepted: 3 July 2020; Published: 7 July 2020 Abstract: The type I interferon (IFN) response is a principal component of our immune system that allows to counter a viral attack immediately upon viral entry into host cells. Upon engagement of aberrantly localised nucleic acids, germline-encoded pattern recognition receptors convey their find via a signalling cascade to prompt kinase-mediated activation of a specific set of five transcription factors. Within the nucleus, the coordinated interaction of these dimeric transcription factors with coactivators and the basal RNA transcription machinery is required to access the gene encoding the type I IFN IFNβ (IFNB1). Virus-induced release of IFNβ then induces the antiviral state of the system and mediates further mechanisms for defence. Due to its key role during the induction of the initial IFN response, the activity of the transcription factor interferon regulatory factor 3 (IRF3) is tightly regulated by the host and fiercely targeted by viral proteins at all conceivable levels. In this review, we will revisit the steps enabling the trans-activating potential of IRF3 after its activation and the subsequent assembly of the multi-protein complex at the IFNβ enhancer that controls gene expression.
    [Show full text]
  • Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendrit
    Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendritic Cells This information is current as of September 28, 2021. Tae Whan Kim, Seunghee Hong, Yin Lin, Elise Murat, HyeMee Joo, Taeil Kim, Virginia Pascual and Yong-Jun Liu J Immunol 2016; 197:3348-3359; Prepublished online 14 September 2016; doi: 10.4049/jimmunol.1502385 Downloaded from http://www.jimmunol.org/content/197/8/3348 Supplementary http://www.jimmunol.org/content/suppl/2016/09/14/jimmunol.150238 http://www.jimmunol.org/ Material 5.DCSupplemental References This article cites 74 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/197/8/3348.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 28, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendritic Cells Tae Whan Kim,*,1 Seunghee Hong,*,1 Yin Lin,* Elise Murat,* HyeMee Joo,* Taeil Kim,†,2 Virginia Pascual,* and Yong-Jun Liu*,† Type I IFNs are crucial mediators of human innate and adaptive immunity and are massively produced from plasmacytoid dendritic cells (pDCs).
    [Show full text]
  • Interferon-Α Therapy in Bcr-Abl-Negative Myeloproliferative Neoplasms
    Leukemia (2008) 22, 1990–1998 & 2008 Macmillan Publishers Limited All rights reserved 0887-6924/08 $32.00 www.nature.com/leu SPOTLIGHT REVIEW Interferon-a therapy in bcr-abl-negative myeloproliferative neoplasms J-J Kiladjian1,2,3, C Chomienne4 and P Fenaux1 1Assistance PubliqueFHoˆpitaux de Paris, Hoˆpital Avicenne, Service d’He´matologie Clinique, Bobigny, France; 2Assistance PubliqueFHoˆpitaux de Paris, Hoˆpital Saint-Louis, Centre d’Investigation Clinique, Paris, France; 3Universite´ Paris 7, Denis Diderot, Paris, France and 4Assistance PubliqueFHoˆpitaux de Paris, Hoˆpital Saint-Louis, Unite´ de Biologie Cellulaire, Paris, France Interferon (IFN) was the first cytokine discovered 50 years ago, however, did not allow complete purity, and although leukocyte with a wide range of biological properties, including immuno- IFN consisted predominantly of IFN-a, small amounts of other modulatory, proapoptotic and antiangiogenic activities, that rapidly raised interest in its therapeutic use in malignancies. IFN species were also present. Later on, the cloning of IFN-receptor characterization was also pivotal in the discovery recombinant human IFN-a and -b in 1980 allowed the SPOTLIGHT of the JAK/STAT signaling pathway. Among the large IFN production of large amounts of IFN for characterization, family, mainly one of the type I IFN, IFN-a2, is used in therapy. biological activity studies and clinical trials.5–7 It is only 20 Many clinical trials have shown remarkable efficacy of IFN-a in years after their discovery that two IFN species, IFN-a and -b, bcr-abl-negative myeloproliferative neoplasms (MPNs), espe- could be purified satisfactorily using high-performance liquid cially polycythemia vera (PV), and essential thrombocythemia 8 (ET).
    [Show full text]
  • IFN-Ε Protects Primary Macrophages Against HIV Infection
    RESEARCH ARTICLE IFN-ε protects primary macrophages against HIV infection Carley Tasker,1 Selvakumar Subbian,2 Pan Gao,3 Jennifer Couret,1 Carly Levine,2 Saleena Ghanny,1 Patricia Soteropoulos,1 Xilin Zhao,1,2 Nathaniel Landau,4 Wuyuan Lu,3 and Theresa L. Chang1,2 1Department of Microbiology, Biochemistry and Molecular Genetics and 2Public Health Research Institute, Rutgers University, New Jersey Medical School, Newark, New Jersey, USA.3Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.4Department of Microbiology, New York University School of Medicine, New York, New York, USA. IFN-ε is a unique type I IFN that is not induced by pattern recognition response elements. IFN-ε is constitutively expressed in mucosal tissues, including the female genital mucosa. Although the direct antiviral activity of IFN-ε was thought to be weak compared with IFN-α, IFN-ε controls Chlamydia muridarum and herpes simplex virus 2 in mice, possibly through modulation of immune response. We show here that IFN-ε induces an antiviral state in human macrophages that blocks HIV-1 replication. IFN-ε had little or no protective effect in activated CD4+ T cells or transformed cell lines unless activated CD4+ T cells were infected with replication-competent HIV-1 at a low MOI. The block to HIV infection of macrophages was maximal after 24 hours of treatment and was reversible. IFN-ε acted on early stages of the HIV life cycle, including viral entry, reverse transcription, and nuclear import. The protection did not appear to operate through known type I IFN-induced HIV host restriction factors, such as APOBEC3A and SAMHD1.
    [Show full text]
  • Heatmaps - the Gene Expression Edition
    Heatmaps - the gene expression edition Jeff Oliver 20 July, 2020 An application of heatmap visualization to investigate differential gene expression. Learning objectives 1. Manipulate data into a ‘tidy’ format 2. Visualize data in a heatmap 3. Become familiar with ggplot syntax for customizing plots Heatmaps for differential gene expression Heatmaps are a great way of displaying three-dimensional data in only two dimensions. But how can we easily translate tabular data into a format for heatmap plotting? By taking advantage of “data munging” and graphics packages, heatmaps are relatively easy to produce in R. Getting started We are going to start by isolating different types of information by imposing structure in our file managment. That is, we are going to put our input data in one folder and any output such as plots or analytical results in a different folder. We can use the dir.create to create these two folders: dir.create("data") dir.create("output") For this lesson, we will use a subset of data on a study of gene expression in cells infected with the influenza virus (doi: 10.4049/jimmunol.1501557). The study infected human plasmacytoid dendritic cells with the influenza virus, and compared gene expression in those cells to gene expression in uninfected cells. Thegoal was to see how the flu virus affected the function of these immune system cells. The data for this lesson is available at: http://tinyurl.com/flu-expression-data or https://jcoliver.github.io/ learn-r/data/GSE68849-expression.csv. Download this comma separated file and put it in the data folder.
    [Show full text]
  • Type I Interferon Suppresses Tumor Growth Through Activating the STAT3-Granzyme B Pathway in Tumor-Infiltrating Cytotoxic T Lymphocytes Chunwan Lu1,2,3*, John D
    Lu et al. Journal for ImmunoTherapy of Cancer (2019) 7:157 https://doi.org/10.1186/s40425-019-0635-8 RESEARCHARTICLE Open Access Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes Chunwan Lu1,2,3*, John D. Klement1,2,3, Mohammed L. Ibrahim1,2,3, Wei Xiao1,2, Priscilla S. Redd1,2,3, Asha Nayak-Kapoor2, Gang Zhou2 and Kebin Liu1,2,3* Abstract Background: Type I interferons (IFN-I) have recently emerged as key regulators of tumor response to chemotherapy and immunotherapy. However, IFN-I function in cytotoxic T lymphocytes (CTLs) in the tumor microenvironment is largely unknown. Methods: Tumor tissues and CTLs of human colorectal cancer patients were analyzed for interferon (alpha and beta) receptor 1 (IFNAR1) expression. IFNAR1 knock out (IFNAR-KO), mixed wild type (WT) and IFNAR1-KO bone marrow chimera mice, and mice with IFNAR1 deficiency only in T cells (IFNAR1-TKO) were used to determine IFN-I function in T cells in tumor suppression. IFN-I target genes in tumor-infiltrating and antigen-specific CTLs were identified and functionally analyzed. Results: IFNAR1 expression level is significantly lower in human colorectal carcinoma tissue than in normal colon tissue. IFNAR1 protein is also significantly lower on CTLs from colorectal cancer patients than those from healthy donors. Although IFNAR1-KO mice exhibited increased susceptibility to methylcholanthrene-induced sarcoma, IFNAR1-sufficient tumors also grow significantly faster in IFNAR1-KO mice and in mice with IFNAR1 deficiency only in T cells (IFNAR1-TKO), suggesting that IFN-I functions in T cells to enhance host cancer immunosurveillance.
    [Show full text]
  • Detecting the Stable Point of Therapeutic Effect of Chronic Myeloid
    Xu et al. BMC Bioinformatics 2019, 20(Suppl 7):202 https://doi.org/10.1186/s12859-019-2738-0 RESEARCH Open Access Detecting the stable point of therapeutic effect of chronic myeloid leukemia based on dynamic network biomarkers Junhua Xu1,MinWu1, Shanshan Zhu1,JinzhiLei2 and Jie Gao1* From The 12th International Conference on Computational Systems Biology (ISB 2018) Guiyang, China. 18-21 August 2018 Abstract Background: Most researches of chronic myeloid leukemia (CML) are currently focused on the treatment methods, while there are relatively few researches on the progress of patients’ condition after drug treatment. Traditional biomarkers of disease can only distinguish normal state from disease state, and cannot recognize the pre-stable state after drug treatment. Results: A therapeutic effect recognition strategy based on dynamic network biomarkers (DNB) is provided for CML patients’ gene expression data. With the DNB criteria, the DNB with 250 genes is selected and the therapeutic effect index (TEI) is constructed for the detection of individual disease. The pre-stable state before the disease condition becomes stable is 1 month. Through functional analysis for the DNB, some genes are confirmed as key genes to affect the progress of CML patients’ condition. Conclusions: The results provide a certain theoretical direction and theoretical basis for medical personnel in the treatment of CML patients, and find new therapeutic targets in the future. The biomarkers of CML can help patients to be treated promptly and minimize drug resistance, treatment failure and relapse, which reduce the mortality of CML significantly. Keywords: Chronic myeloid leukemia (CML), Dynamic network biomarkers (DNB), Differentially expressed genes (DEGs), Therapeutic effect index (TEI), Pre-stable state, Treatment time Introduction At present, the use of ABL kinase inhibitors (e.g.
    [Show full text]
  • CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity a C Suresh De Silva, George Fromm, Casey W
    Published OnlineFirst December 18, 2019; DOI: 10.1158/2326-6066.CIR-19-0493 CANCER IMMUNOLOGY RESEARCH | RESEARCH ARTICLE CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity A C Suresh de Silva, George Fromm, Casey W. Shuptrine, Kellsey Johannes, Arpita Patel, Kyung Jin Yoo, Kaiwen Huang, and Taylor H. Schreiber ABSTRACT ◥ Disrupting the binding of CD47 to SIRPa has emerged as a No evidence of hemolysis, hemagglutination, or thrombocytopenia promising immunotherapeutic strategy for advanced cancers by was observed in vitro or in cynomolgus macaques. Murine SIRPa- potentiating antibody-dependent cellular phagocytosis (ADCP) of Fc-CD40L outperformed CD47 blocking and CD40 agonist anti- targeted antibodies. Preclinically, CD47/SIRPa blockade induces bodies in murine CT26 tumor models and synergized with immune antitumor activity by increasing the phagocytosis of tumor cells by checkpoint blockade of PD-1 and CTLA4. SIRPa-Fc-CD40L acti- macrophages and enhancing the cross-presentation of tumor anti- vated a type I interferon response in macrophages and potentiated þ gens to CD8 T cells by dendritic cells; both of these processes are the activity of ADCP-competent targeted antibodies both in vitro and potentiated by CD40 signaling. Here we generated a novel, two-sided in vivo. These data illustrated that whereas CD47/SIRPa inhibition fusion protein incorporating the extracellular domains of SIRPa and could potentiate tumor cell phagocytosis, CD40-mediated activation CD40L, adjoined by a central Fc domain, termed SIRPa-Fc-CD40L. of a type I interferon response provided a bridge between macro- SIRPa-Fc-CD40L bound CD47 and CD40 with high affinity and phage- and T-cell–mediated immunity that significantly enhanced activated CD40 signaling in the absence of Fc receptor cross-linking.
    [Show full text]
  • Chemotherapy Followed by Anti-CD137 Mab Immunotherapy Improves Disease Control in a Mouse Myeloma Model
    Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model Camille Guillerey, … , Ludovic Martinet, Mark J. Smyth JCI Insight. 2019;4(14):e125932. https://doi.org/10.1172/jci.insight.125932. Research Article Immunology Immunotherapy holds promise for patients with multiple myeloma (MM), but little is known about how MM-induced immunosuppression influences response to therapy. Here, we investigated the impact of disease progression on immunotherapy efficacy in the Vk*MYC mouse model. Treatment with agonistic anti-CD137 (4-1BB) mAbs efficiently protected mice when administered early but failed to contain MM growth when delayed more than 3 weeks after Vk*MYC tumor cell challenge. The quality of the CD8+ T cell response to CD137 stimulation was not altered by the presence of MM, but CD8+ T cell numbers were profoundly reduced at the time of treatment. Our data suggest that an insufficient ratio of CD8+ T cells to MM cells (CD8/MM ratio) accounts for the loss of anti-CD137 mAb efficacy. We established serum M- protein levels prior to therapy as a predictive factor of response. Moreover, we developed an in silico model to capture the dynamic interactions between CD8+ T cells and MM cells. Finally, we explored two methods to improve the CD8/MM ratio: anti-CD137 mAb immunotherapy combined with Treg depletion or administered after chemotherapy treatment with cyclophosphamide or melphalan efficiently reduced MM burden and prolonged survival. Together, our data indicate that consolidation treatment with anti-CD137 mAbs might prevent MM relapse. Find the latest version: https://jci.me/125932/pdf RESEARCH ARTICLE Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model Camille Guillerey,1,2,3 Kyohei Nakamura,1 Andrea C.
    [Show full text]